Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2639-2648

  Cobleigh, Melody A ^a   Vogel, Charles L ^a   Tripathy, Debu ^a   Robert, Nicholas J ^a   Scholl, Susy ^a   Fehrenbacher, Louis ^a   Wolter, Janet M ^a   Paton, Virginia ^a   Shak, Steven ^a   Lieberman, Gracie ^a   Slamon, Dennis J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; ONCOPROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0032850677     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2639     Document Type: Article

References (27)

1. Aaronson SA: Growth factors and cancer. Science 254:1146-1153, 1991
2. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
3. Akiyama T, Sudo C, Ogawara H, et al: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986
4. Stern DF, Heffernan PA, Weinberg RA: p 185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol 6:1729-1740, 1986
5. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
6. Slamon DJ, Godolphin W, Jones LA, et al: Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
7. Hynes NE, Stern DF: The biology of erB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184, 1994
8. Ravdin PM, Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review. Gene 159: 19-27, 1995
9. Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159-7163, 1987
10. Di Fiore PP, Pierce JH, Kraus MH, et al: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182, 1987
11. Guy CT, Webster MA, Schaller M, et al: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89:10578-10582, 1992
12. Hudziak RM, Lewis GD, Winget M, et al: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165-1172, 1989
13. McKenzie SJ, Marks PJ, Lam T, et al: Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4:543-548, 1989
14. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991
15. Harwerth IM, Wels W, Schlegel J, et al: Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 68:1140-1145, 1993
16. HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285-4289, 1992
17. HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
18. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
19. ® (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998 (abstr 377)
20. ® (trasutzumab) clinical trials. Breast Cancer Res Treat 50:232a, 1998 (abstr)
21. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
22. Vogel CL: Current status of salvage chemotherapy for refractory advanced breast cancer. Oncology 10:7-15, 1996 (suppl)
23. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567-2574, 1995
24. Abrams JS, Vena DA, Baltz J, et al: Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13:2056-2065, 1995
25. ® (docetaxel) prescribing information. Collegeville, PA, Rhône-Poulenc Rorer, 1996
26. Shan K, Lincoff AM, Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58, 1996
27. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979